Applied StemCell raises $19M in series D

Applied StemCell Inc. (Milpitas, Calif.) raised $19 million in a series D round led by HerMed Capital. Ping An Ventures, Vi Ventures and BioSciKin, a subsidiary of Simcere Pharmaceutical Group (Nanjing, China), also participated.

Applied StemCell is developing gene therapy programs in undisclosed monogenic blood diseases based on site-specific gene editing technology licensed from Stanford University. CEO Ruhong Jiang told BioCentury the company is conducting first-in-human studies in China and the U.S. ...